5-ht3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial

Authors

neyousha mohammadi

maryam noroozian

naregs karamghadiri

shahin akhondzadeh

abstract

introduction: patients with schizophrenia characteristically exhibit cognitive deficits. the level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. the purpose of this study was to assess the efficacy of ondansetron, a 5-ht3 receptor antagonist as an adjuvant agent in the treatment of chronic schizophrenia in particular for cognitive impairments. methods: this investigation was a 12-week, double blind study of parallel groups of patients with stable chronic schizophrenia. thirty patients were recruited from inpatient and outpatient departments. all participants met diagnostic and statistical manual of mental disorders fourth edition, text revision (dsm-iv-tr) criteria for schizophrenia. to be eligible, patients were required to have been treated with a stable dose of risperidone as their primary antipsychotic treatment for a minimum period of 8 weeks. the subjects were randomized to receive ondansetron (8 mg/day) or the placebo in addition to risperidone. cognition was measured by a cognitive battery. patients were assessed at baseline and after 8, and 12 weeks after the medication started. results: administration of ondansetron significantly improved visual memory based on improvement on visual reproduction, visual paired associate and figural memory sub tests of wechsler memory scale revised. discussion: the present study indicates ondansetron as potential adjunctive treatment strategy for chronic schizophrenia particularly for cognitive impairments.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial

Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic...

full text

Effect of Memantine on Positive Sign in Patients with Schizophrenia and Schizoaffective Disorders: A Randomized Double Blind Placebo Controlled Trial

Background and purpose: Memantine is a medication used to treat moderate to severe Alzheimer’s disease. Memantine targeting the glutamatergic system specifically N-Methyl-D-Aspartate offer a novel approach in treatment of psychiatric disorders such as schizophrenia and schizoaffective disorder. The purpose of this study was to evaluate the efficacy and safety of memantine in combination with an...

full text

Treatment-Responsiveness of Negative Symptoms in Schizophrenia: A double-blind placebo-control clinical trial

Background: The negative symptoms of schizophrenia remain a major clinical challenge. Nortriptyline is a serotonin and noradrenalin reuptake inhibitor and belongs to secondary amine tricycles. The aim of this study is to evaluate the effect of nortriptyline on the negative symptoms of schizophrenia. Methods: This study is a six-week randomized placebo-control trial of nortriptyline or placebo a...

full text

Methoxsalen bath in the treatment of palmoplantar Eczema: A double-blind, placebo controlled clinical trial

Background: Palmoplantar eczema is a common clinical problem involving 2% of the population. There are many treatment modalities for palmoplantar eczema, each with specific local and systemic side effects. Objective: To evaluate methoxsalen bath in the treatment of palmoplantar eczema. Patients and Methods: In a randomized, double-blind, placebo controlled clinical trial, 60 patients with palmo...

full text

Azithromycin in Pityriasis Rosea: A Double-Blind, Placebo-Controlled Clinical Trial

Background: Pityriasis rosea is an inflammatory skin disorder with a known response to erythromycin. Considering similarities between erythromycin and azithromycin and lesser adverse effects of the latter, in a pilot study, we gave azithromycin to seven patients with pityriasis rosea and observed a noticeable improvement. The aim of this study was to evaluate the efficacy of azithromycin ...

full text

A double-blind, placebo-controlled trial

not all patients underwent regular follow-up endoscopy .after apparent healing. In adults it is now well known that many relapses are entirely asymptomatic and it is possible that the same applies in children. After initial diagnosis and treatment, no patient subsequently presented with complications of gastro-intestinal bleeding or perforation. It would seem that the consequences of missing an...

full text

My Resources

Save resource for easier access later


Journal title:
basic and clinical neuroscience

جلد ۱، شماره ۲، صفحات ۱۰-۱۴

Keywords
[ ' c o g n i t i v e i m p a i r m e n t s ' , 5 , ' h t 3 ' , ' s c h i z o p h r e n i a ' ]

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023